When is a pill a pill? – Teva Pharmaceuticals
A drug company is taking a gamble on a new drug that’s been hailed as a breakthrough in a field that has struggled to understand why women are getting sicker and more ill.
The new drug, called teva-6-tetrahydrofolate, is a combination of three of the most promising ingredients in existing treatments, but the drug’s creators say the combination is especially effective in preventing cardiovascular disease.
The drug’s makers say it will treat heart attacks, strokes, and kidney stones.
But some doctors are not so optimistic.
Dr. Steven M. Wittenberg, a cardiologist at Northwestern University, said the drug would likely have little to no benefit for women.
“The drug that we are seeing is not very good,” he said.
“It’s not going to be good for women in terms of prevention of heart attacks.”
But the drug makers say that because of its combination of ingredients, it is not only a safe alternative to standard heart attacks and strokes treatments, it also has a much lower risk of causing serious side effects like kidney stones and high blood pressure.
It could be used in the first trimester, they say.
And it will not be used for the first few years of pregnancy.
For the most part, women who take the drug for the treatment of heart attack or stroke will not need to take another drug to control their blood pressure or prevent kidney stones, the makers say.
“This is a very safe and effective medication for women, and it will have a very low risk of side effects, including kidney stones,” Dr. Witty said.
“If we continue to use this medicine, we are not going get a heart attack.”
The FDA has not approved the drug, which is a joint effort by Teva and the National Institutes of Health.
But it has been approved by several health organizations and experts, including the American College of Cardiology and the American Heart Association.
The makers say they will be able to start the clinical trial with about 10,000 patients in the United States and the United Kingdom by the end of this year.
Teva plans to spend $20 million to cover the first phase of the trial.
The company says it will be a breakthrough drug, but some experts are skeptical.
“I think it’s very important that we continue this dialogue, because we’re on the cusp of a lot of big breakthroughs that we may not be able access,” Dr Wittenburg said.
Teva is developing a drug to treat blood clots, and is working on another one to treat pulmonary hypertension.
Tevas is also developing a pill that could help prevent blood clotting, which could be a major benefit for those who already have heart disease.
And the drug company says its drug will be effective in treating blood clogged arteries in patients with type 2 diabetes.
It’s one of many new drugs the company is working to develop.
Tevas new drug is expected to be available by 2020.
Copyright © 2018 The Associated Press.
All rights reserved.
This material may not appear in print, on screen, or in print forms without permission.